Robert Grieve

6.5k total citations · 2 hit papers
68 papers, 3.8k citations indexed

About

Robert Grieve is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Robert Grieve has authored 68 papers receiving a total of 3.8k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Oncology, 12 papers in Surgery and 10 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Robert Grieve's work include Cancer Treatment and Pharmacology (11 papers), Breast Cancer Treatment Studies (9 papers) and Colorectal and Anal Carcinomas (8 papers). Robert Grieve is often cited by papers focused on Cancer Treatment and Pharmacology (11 papers), Breast Cancer Treatment Studies (9 papers) and Colorectal and Anal Carcinomas (8 papers). Robert Grieve collaborates with scholars based in United Kingdom, United States and Canada. Robert Grieve's co-authors include David Sebag‐Montefiore, Philip Quirke, Jean Couture, Richard Stephens, Lindsay C Thompson, R. Steele, Arthur Sun Myint, Mahesh Parmar, John R.T. Monson and Subhash Khanna and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Gastroenterology.

In The Last Decade

Robert Grieve

65 papers receiving 3.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial

2009 1.1k citations David Sebag‐Montefiore, Robert Grieve et al. profile →
Effect of the plane of surgery achieved on local recurrence in patients with operable rectal cancer: a prospective study using data from the MRC CR07 and NCIC-CTG CO16 randomised clinical trial

2009 708 citations Philip Quirke, Robert Grieve et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Robert Grieve United Kingdom	25	2.7k	1.7k	660	357	320	68	3.8k
John P. Curtin United States	39	1.1k 0.4×	1.8k 1.0×	556 0.8×	229 0.6×	154 0.5×	185	5.4k
Jean‐Noël Talbot France	38	1.0k 0.4×	970 0.6×	1.7k 2.5×	474 1.3×	1.9k 5.9×	232	5.5k
Dong‐Hoon Yang South Korea	44	1.6k 0.6×	2.1k 1.2×	1.6k 2.4×	146 0.4×	174 0.5×	374	6.8k
Jung Young Lee South Korea	28	943 0.3×	350 0.2×	553 0.8×	496 1.4×	188 0.6×	92	2.6k
Giuseppe Catalano Italy	27	1.1k 0.4×	359 0.2×	842 1.3×	295 0.8×	153 0.5×	108	2.6k
Mark Jeffery New Zealand	19	1.2k 0.4×	259 0.2×	492 0.7×	257 0.7×	188 0.6×	77	2.1k
Josep Llach Spain	45	1.0k 0.4×	3.1k 1.8×	1.4k 2.1×	51 0.1×	134 0.4×	233	7.4k
Roger Williams United Kingdom	52	618 0.2×	2.4k 1.4×	629 1.0×	197 0.6×	75 0.2×	259	8.8k
Antonella Petrillo Italy	42	1.8k 0.7×	992 0.6×	1.1k 1.7×	439 1.2×	2.6k 8.1×	275	5.9k
Terence M. Williams United States	47	2.3k 0.8×	918 0.5×	1.5k 2.2×	1.5k 4.3×	367 1.1×	223	7.7k

Countries citing papers authored by Robert Grieve

Since Specialization

Citations

This map shows the geographic impact of Robert Grieve's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Grieve with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Grieve more than expected).

Fields of papers citing papers by Robert Grieve

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert Grieve. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Grieve. The network helps show where Robert Grieve may publish in the future.

Co-authorship network of co-authors of Robert Grieve

This figure shows the co-authorship network connecting the top 25 collaborators of Robert Grieve. A scholar is included among the top collaborators of Robert Grieve based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert Grieve. Robert Grieve is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Grieve, Robert, et al.. (2017). Human capital challenges in the hotel industry of Canada: finding innovative solutions. Worldwide Hospitality and Tourism Themes. 9(4). 402–410. 6 indexed citations

Morris, Stephen, Julia Scarisbrick, J. Frew, et al.. (2017). The Results of Low-Dose Total Skin Electron Beam Radiation Therapy (TSEB) in Patients With Mycosis Fungoides From the UK Cutaneous Lymphoma Group. International Journal of Radiation Oncology*Biology*Physics. 99(3). 627–633. 54 indexed citations

Bayani, Jane, James P. Morden, Peter Bliss, et al.. (2015). Abstract P4-11-03: Androgen receptor expression is an independent marker of lower residual risk in the TACT2 trial (CRUK/05/019). Cancer Research. 75(9_Supplement). P4–11. 1 indexed citations

Gollins, Simon, David Sebag‐Montefiore, Richard Adams, et al.. (2015). A phase II single arm feasibility trial of neoadjuvant chemotherapy (NAC) with oxaliplatin/fluorouracil (OxMdG) then short-course preoperative radiotherapy (SCPRT) then immediate surgery in operable rectal cancer (ORC): COPERNICUS (NCT01263171).. Journal of Clinical Oncology. 33(15_suppl). 3609–3609. 6 indexed citations

Coleman, Robert E., David Cameron, David Dodwell, et al.. (2014). Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial. The Lancet Oncology. 15(9). 997–1006. 202 indexed citations

Barrett‐Lee, Peter, Angela Casbard, Jacinta Abraham, et al.. (2013). Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial. The Lancet Oncology. 15(1). 114–122. 83 indexed citations

Sebag‐Montefiore, David, Helen Meadows, David Cunningham, et al.. (2012). Three cytotoxic drugs combined with pelvic radiation and as maintenance chemotherapy for patients with squamous cell carcinoma of the anus (SCCA): Long-term follow-up of a phase II pilot study using 5-fluorouracil, mitomycin C and cisplatin. Radiotherapy and Oncology. 104(2). 155–160. 23 indexed citations

Damery, Sarah, Christine Gratus, Robert Grieve, et al.. (2011). The use of herbal medicines by people with cancer: a cross-sectional survey. British Journal of Cancer. 104(6). 927–933. 83 indexed citations

Mills, John A., et al.. (2011). A preliminary comparison of total skin electron treatment techniques to demonstrate the application of a mid-torso phantom for measurement of dose penetration. British Journal of Radiology. 84(1008). 1125–1130. 7 indexed citations

10.

Coleman, RE, Jane Brown, David Cameron, et al.. (2010). Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE–BIG 01–04) for women with stage II/III breast cancer. Bone. 48(1). S29–S29. 10 indexed citations

11.

Sanghera, Paul, et al.. (2010). A Study of Medical Intervention in Routine Breast Cancer Follow-up. Clinical Oncology. 22(2). 91–96. 2 indexed citations

12.

Gratus, Christine, Sue Wilson, Sheila Greenfield, et al.. (2009). The use of herbal medicines by people with cancer: a qualitative study. BMC Complementary and Alternative Medicine. 9(1). 14–14. 57 indexed citations

13.

Gratus, Christine, Sarah Damery, Sue Wilson, et al.. (2009). The use of herbal medicines by people with cancer in the UK: a systematic review of the literature. QJM. 102(12). 831–842. 29 indexed citations

14.

Earl, Helena, Louise Hiller, Janet Dunn, et al.. (2007). The National Epirubicin Adjuvant Trial (NEAT) and Scottish Cancer Trials Breast Group (SCTBG) br9601 randomized phase III adjuvant early breast cancer trials: The updated definitive joint analysis. Journal of Clinical Oncology. 25(18_suppl). 534–534. 1 indexed citations

15.

Twelves, Chris, Simon Gollins, Robert Grieve, & Leslie Samuel. (2005). A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer. Annals of Oncology. 17(2). 239–245. 126 indexed citations

16.

Rea, Daniel, Louise Hiller, Helena Earl, et al.. (2004). Tolerability and efficacy of classical CMF (cCMF) using oral cyclophosphamide (OC) vs intravenous cyclophosphamide (IVC) in early stage breast cancer: A non-randomised comparison of patients (pts) treated in the National Epirubicin Adjuvant Trial (NEAT). Journal of Clinical Oncology. 22(14_suppl). 595–595. 2 indexed citations

17.

Mynors, Diane, P. Broomhead, & Robert Grieve. (2004). Web-based material properties for use with metalforming simulation packages. Journal of Materials Processing Technology. 153-154. 688–693. 3 indexed citations

18.

Giridharan, Selvaraj, J I Geh, J. Glaholm, et al.. (2004). Multicentre prospective audit of surgical outcomes and acute complications following short course pre‐operative radiotherapy for resectable rectal cancer. Colorectal Disease. 7(1). 43–46. 5 indexed citations

19.

Irani, Zahir, et al.. (1999). A case study strategy as part of an information systems research methodology: a critique. International Journal of Computer Applications in Technology. 12(2/3/4/5). 190–190. 30 indexed citations

20.

Gunasekaran, A., Hussain Bux Marri, & Robert Grieve. (1999). Justification and implementation of activity based costing in small and medium‐sized enterprises. Logistics Information Management. 12(5). 386–394. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact